IL250110B - Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer - Google Patents

Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer

Info

Publication number
IL250110B
IL250110B IL250110A IL25011017A IL250110B IL 250110 B IL250110 B IL 250110B IL 250110 A IL250110 A IL 250110A IL 25011017 A IL25011017 A IL 25011017A IL 250110 B IL250110 B IL 250110B
Authority
IL
Israel
Prior art keywords
aflibercept
outcome
suffer
estimating
cancer
Prior art date
Application number
IL250110A
Other languages
English (en)
Hebrew (he)
Other versions
IL250110A0 (en
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of IL250110A0 publication Critical patent/IL250110A0/en
Publication of IL250110B publication Critical patent/IL250110B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G01N33/57535—
    • G01N33/5758—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5421—IL-8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL250110A 2014-07-18 2017-01-15 Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer IL250110B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14306172 2014-07-18
PCT/EP2015/066262 WO2016008975A1 (en) 2014-07-18 2015-07-16 Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer

Publications (2)

Publication Number Publication Date
IL250110A0 IL250110A0 (en) 2017-03-30
IL250110B true IL250110B (en) 2020-04-30

Family

ID=51220534

Family Applications (1)

Application Number Title Priority Date Filing Date
IL250110A IL250110B (en) 2014-07-18 2017-01-15 Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer

Country Status (25)

Country Link
US (2) US10501523B2 (OSRAM)
EP (1) EP3170005B1 (OSRAM)
JP (1) JP6685276B2 (OSRAM)
KR (1) KR102486321B1 (OSRAM)
CN (1) CN107076750B (OSRAM)
AU (1) AU2015289124B2 (OSRAM)
CY (1) CY1122233T1 (OSRAM)
DK (1) DK3170005T3 (OSRAM)
EA (1) EA035674B1 (OSRAM)
ES (1) ES2732925T3 (OSRAM)
HR (1) HRP20191145T1 (OSRAM)
HU (1) HUE043951T2 (OSRAM)
IL (1) IL250110B (OSRAM)
LT (1) LT3170005T (OSRAM)
MA (1) MA40354A (OSRAM)
MX (1) MX375557B (OSRAM)
PL (1) PL3170005T3 (OSRAM)
PT (1) PT3170005T (OSRAM)
RS (1) RS58957B1 (OSRAM)
SG (1) SG11201700284UA (OSRAM)
SI (1) SI3170005T1 (OSRAM)
TR (1) TR201909951T4 (OSRAM)
TW (1) TWI705247B (OSRAM)
WO (1) WO2016008975A1 (OSRAM)
ZA (1) ZA201700371B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP6685276B2 (ja) 2014-07-18 2020-04-22 サノフイＳａｎｏｆｉ 癌に罹患していることが疑われる患者のアフリベルセプトを用いた処置の結果を予測するための方法
NZ744185A (en) 2015-12-30 2025-09-26 Kodiak Sciences Inc Antibodies and conjugates thereof
CN108496084B (zh) * 2016-01-25 2021-11-05 赛诺菲 通过测量血浆生物标记的水平预测疑似患有癌症的患者使用阿柏西普的治疗的结果的方法
CN107602702A (zh) * 2017-09-22 2018-01-19 生标（上海）医疗器械科技有限公司 一种同时靶向人p185和血管内皮生长因子的抗体及其应用
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
PT4364724T (pt) 2018-05-10 2025-12-16 Regeneron Pharma Formulações contendo uma proteína de fusão do recetor do vegf de concentração elevada
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
KR102720956B1 (ko) * 2020-12-15 2024-10-24 삼천당제약주식회사 안과용 제형을 포함하는 시린지
WO2023153535A1 (ko) * 2022-02-09 2023-08-17 삼천당제약주식회사 안과용 제형을 포함하는 시린지

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353887A (en) 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
WO1993000807A1 (en) 1991-07-03 1993-01-21 Cryolife, Inc. Method for stabilization of biomaterials
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
AU670793B2 (en) 1992-04-30 1996-08-01 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor VIII complex
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
JP3734262B2 (ja) 1993-03-25 2006-01-11 メルク エンド カンパニー インコーポレーテッド 血管内皮細胞増殖因子阻害剤
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
GB9410534D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
GB9410533D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
IL117684A (en) 1995-04-07 2002-02-10 Pharmacia & Upjohn Inc Intermediates and Process for Production of History of Kempotocin (CPT-11) and Related Compounds
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JPH09154588A (ja) 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
ATE343400T1 (de) 1996-09-24 2006-11-15 Merck & Co Inc Verbindungen zur hemmung der angiogenese durch gentherapie
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
DE19724793A1 (de) 1997-06-06 1998-12-10 Schering Ag D-mutierte Peptide mit VEGF-Rezeptor blockierenden Eigenschaften
US6075007A (en) 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
JPH1180024A (ja) 1997-09-12 1999-03-23 Toagosei Co Ltd 角膜血管新生阻害剤
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
DE19841985A1 (de) 1998-09-03 2000-03-09 Schering Ag Dialkylsulfonsäure- und Dialkylcarbonsäure-Derivate
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
WO2000034337A1 (en) 1998-12-10 2000-06-15 Tsukuba Research Laboratory, Toagosei Co., Ltd. Humanized monoclonal antibodies against vascular endothelial cell growth factor
AP1243A (en) 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.
US6342219B1 (en) 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
WO2000066125A1 (en) 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
CN100523187C (zh) 1999-06-08 2009-08-05 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
DE19938724A1 (de) 1999-08-16 2001-02-22 Tetra Laval Holdings & Finance Vorrichtung zur Herstellung von Kunststoffbehältern mittels Streckblasformen
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US6500633B1 (en) 2000-04-26 2002-12-31 Atairgin Technologies, Inc. Method of detecting carcinomas
AR028424A1 (es) 2000-05-10 2003-05-07 Bayer Corp Metodo para regular la angiogenesis utilizando proteina ryk
ATE442862T2 (de) 2000-10-12 2009-10-15 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US20030092019A1 (en) 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
US20040023864A1 (en) 2001-05-09 2004-02-05 Steve Roczniak Method of regulating angiogenesis using ryk protein
EP1409018B1 (en) 2001-07-25 2010-01-06 Facet Biotech Corporation Stable lyophilized pharmaceutical formulation the igg antibody daclizumab
JP2005525367A (ja) 2002-03-01 2005-08-25 フアルマシア・イタリア・エツセ・ピー・アー 塩酸イリノテカンの結晶多形
JP2004006671A (ja) 2002-03-22 2004-01-08 Sanyo Electric Co Ltd 電荷結合素子およびその製造方法
DK1608685T3 (da) 2003-03-28 2007-06-11 Regeneron Pharma VEGF antagonister til behandlingen af diabetes
RU2332986C2 (ru) 2003-04-04 2008-09-10 Дженентек, Инк. Высококонцентрированные композиции антител и белков
US7300654B2 (en) 2003-05-28 2007-11-27 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection in high risk keratoplasty patients
EP1626989A2 (en) 2003-05-28 2006-02-22 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection by using vegf antagonists
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
WO2004110490A2 (en) 2003-06-06 2004-12-23 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for tumor regression
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
US20050196340A1 (en) 2003-08-06 2005-09-08 Jocelyn Holash Use of a VEGF antagonist in combination with radiation therapy
CA2534197A1 (en) 2003-08-06 2005-02-24 Thomas Jefferson University Use of a vegf antagonist in combination with radiation therapy
NZ617083A (en) 2003-08-27 2015-04-24 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
ATE423670T1 (de) 2003-11-06 2009-03-15 Nestle Waters Man & Technology Herstellungsverfahren von behältern aus polyesterharz
US7582726B2 (en) 2003-11-10 2009-09-01 Ghc Research Development Corporation VEGF receptor antagonists
WO2005072772A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
CA2567686A1 (en) 2004-06-10 2005-12-29 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for the treatment of human cancer
WO2006009809A2 (en) 2004-06-18 2006-01-26 Regeneron Pharmaceuticals, Inc. Vegf inhibitors for the treatment of malignant pleural effusion
WO2006015297A2 (en) 2004-07-30 2006-02-09 Regeneron Pharmaceuticals, Inc. Methods of treating type i diabetes by blocking vegf-mediated activity
WO2006047325A1 (en) 2004-10-21 2006-05-04 Genentech, Inc. Method for treating intraocular neovascular diseases
FR2878749B1 (fr) 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
EP1877438A2 (en) 2005-02-02 2008-01-16 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
CA2597247A1 (en) 2005-02-11 2006-08-17 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
CA2598452A1 (en) 2005-03-11 2006-09-21 Regeneron Pharmaceuticals, Inc. Treating anemia by inhibition of vegf
LT2586459T (lt) 2005-03-25 2017-09-25 Regeneron Pharmaceuticals, Inc. Vegf antagonisto kompozicijos
US7531172B2 (en) 2005-08-12 2009-05-12 Regeneron Pharmaceuticals, Inc. Methods of treating diseases with a VEGF antagonist
US7354582B2 (en) 2006-03-10 2008-04-08 Regeneron Pharmaceuticals, Inc. Use of VEGF antagonists for the treatment of malignant gliomas
CN104434770A (zh) 2006-06-16 2015-03-25 瑞泽恩制药公司 适合玻璃体内施用的vegf拮抗剂的制剂
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
WO2008118846A1 (en) * 2007-03-23 2008-10-02 Precision Therapeutics, Inc. Methods for evaluating angiogenic potential in culture
FR2918279B1 (fr) 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
EA018973B1 (ru) 2007-10-04 2013-12-30 Оникс Терапьютикс, Инк. Кристаллические пептидные кето-эпоксидные ингибиторы протеаз и синтез кето-эпоксидов аминокислот
WO2009058908A2 (en) * 2007-10-29 2009-05-07 Eisai R & D Management Co., Ltd. Methods for prognosing the ability of a zearalenone analog compound to treat cancer
ATE522809T1 (de) 2007-11-30 2011-09-15 Genentech Inc Vegf-polymorphismen und antiangiogenese-therapie
EP2143542A1 (fr) 2008-07-07 2010-01-13 Nestec S.A. Procédé et dispositif de conditionnement d'un liquide alimentaire
FR2933702A1 (fr) 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
WO2010022201A2 (en) 2008-08-22 2010-02-25 Osteogenex Inc. Folinic acid derivatives for promoting bone growth
EP2347256A4 (en) 2008-10-09 2012-02-08 Alfagene Bioscience Inc USE AND IDENTIFY BIOMARKERS FOR STOMACH DISEASES
CN103333952B (zh) 2008-11-05 2015-07-29 健泰科生物技术公司 年龄相关的黄斑变性中的遗传多态性
JP2012518680A (ja) 2009-03-31 2012-08-16 ロシュ グリクアート アクチェンゲゼルシャフト ヒト化抗ＥＧＦＲＩｇＧ１抗体及びイリノテカンによる癌の処置
WO2010124264A2 (en) 2009-04-24 2010-10-28 University Of Southern California Genetic variants in angiogenesis pathway associated with clinical outcome
BR112012000735A2 (pt) * 2009-07-13 2016-11-16 Genentech Inc "métodos, kits e conjuntos de compostos"
EP2459456B1 (en) 2009-07-31 2018-04-25 Amcor Group GmbH Hot-fill container
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
KR20120104196A (ko) * 2009-10-02 2012-09-20 사일린 파마슈티칼스, 인크 Ｃｋ2 저해제에 대한 단백질 키나아제 ｃｋ2-매개의 질환의 감수성 및 반응을 예측하기 위한 바이오마커
US20120264803A1 (en) * 2009-12-25 2012-10-18 Toshinori Oka Method for predicting therapeutic effects of chemotherapy on hepatocellular carcinoma patients
ES2653646T3 (es) * 2010-07-14 2018-02-08 Vision Tech Bio Pty Ltd Diagnóstico para cáncer colorrectal
WO2012123227A1 (en) 2011-02-23 2012-09-20 Sanofi Single nucleotide polymorphisms in the promoter of vegfa gene and their use as predictive markers for anti-vegf treatments
TWI671315B (zh) * 2011-03-28 2019-09-11 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
JO3283B1 (ar) * 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
ES2841809T3 (es) * 2011-06-03 2021-07-09 Eisai R&D Man Co Ltd Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
EP2844270A4 (en) * 2012-03-15 2016-01-27 Univ New York State Res Found COMBINATION THERAPIES WITH INHIBITORS OF THE EXTRACELLULAR DOMAIN OF E-CADHERINE
JP6019790B2 (ja) 2012-06-19 2016-11-02 富士電機株式会社 接合方法及び接合部材
AR091967A1 (es) 2012-08-02 2015-03-11 Sanofi Sa Articulo de fabricacion que comprende aflibercept o 2iv-aflibercept
JP6685276B2 (ja) 2014-07-18 2020-04-22 サノフイＳａｎｏｆｉ 癌に罹患していることが疑われる患者のアフリベルセプトを用いた処置の結果を予測するための方法
CN108496084B (zh) 2016-01-25 2021-11-05 赛诺菲 通过测量血浆生物标记的水平预测疑似患有癌症的患者使用阿柏西普的治疗的结果的方法

Also Published As

Publication number Publication date
MA40354A (fr) 2017-05-24
KR102486321B1 (ko) 2023-01-09
DK3170005T3 (da) 2019-07-08
RS58957B1 (sr) 2019-08-30
PL3170005T3 (pl) 2019-10-31
JP2017524127A (ja) 2017-08-24
WO2016008975A1 (en) 2016-01-21
AU2015289124A1 (en) 2017-02-09
CY1122233T1 (el) 2020-11-25
HUE043951T2 (hu) 2019-09-30
KR20170030631A (ko) 2017-03-17
EP3170005B1 (en) 2019-04-10
SI3170005T1 (sl) 2019-08-30
US11208461B2 (en) 2021-12-28
EA035674B1 (ru) 2020-07-24
AU2015289124B2 (en) 2021-03-11
SG11201700284UA (en) 2017-02-27
US10501523B2 (en) 2019-12-10
IL250110A0 (en) 2017-03-30
CA2955302A1 (en) 2016-01-21
TWI705247B (zh) 2020-09-21
JP6685276B2 (ja) 2020-04-22
US20170121387A1 (en) 2017-05-04
US20200157181A1 (en) 2020-05-21
EP3170005A1 (en) 2017-05-24
TW201619608A (zh) 2016-06-01
CN107076750A (zh) 2017-08-18
MX2017000840A (es) 2017-05-04
MX375557B (es) 2025-03-06
ZA201700371B (en) 2019-12-18
LT3170005T (lt) 2019-07-10
HRP20191145T1 (hr) 2019-10-04
EA201790211A1 (ru) 2017-05-31
TR201909951T4 (tr) 2019-07-22
CN107076750B (zh) 2020-06-23
PT3170005T (pt) 2019-07-16
ES2732925T3 (es) 2019-11-26

Similar Documents

Publication Publication Date Title
IL285965A (en) Ex vivo organ care system
IL296080B1 (en) Method for treating cancer
IL255261A0 (en) Methods for treating cancer
IL251890A0 (en) Combination immunotherapy approach for treatment of cancer
IL250110B (en) Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
ZA201703290B (en) Methods for tumor treatment using cd3xcd20 bispecific antibody
HUE054397T2 (hu) Antitestkészítmények daganatkezelésre
SG11201701723XA (en) Methods of treating liver disease
PT3212233T (pt) Terapia combinada para o tratamento de doenças
GB201701673D0 (en) Methods of well treatment
HUE038541T2 (hu) Rák kezelési módszerek
IL247354A0 (en) Treatment of conditions associated with hyperinsulinaemia
PL3186244T3 (pl) Analogi dioksolanowe urydyny w leczeniu raka
EP3215219C0 (en) SKIN TREATMENT SYSTEM
IL248767B (en) Trimethoxyphenyl-benzaimidazole compounds for cancer treatment
PL3134119T3 (pl) Leczenie nowotworu
IL251903B (en) Apilimod for use in the treatment of colorectal cancer
LT3119384T (lt) Intrahepatinių cholestazinių ligų gydymas
HUE054998T2 (hu) Kombinációs terápiák emlõrák kezelésében való alkalmazásra
IL246558A0 (en) Novel methods for treating cancer
GB201409363D0 (en) Skin cancer treatment
IL252707A0 (en) Compositions and methods for treating diseases and conditions
GB201405449D0 (en) Treatment of cancer
GB201405075D0 (en) Treatment of cancer

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed